Analyst Reco. Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
34.00 ^USD	-0.96%		+5.72%	-1.19%

Jun. 11	Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025	CI
Jun. 09	Harmony Biosciences Holdings, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03:20 PM

Analyst Reco.

Mizuho Raises Price Target on Harmony Biosciences to $48 From $44, Keeps Outperform Rating	May. 15	MT
UBS Adjusts Price Target on Harmony Biosciences to $48 From $55, Maintains Buy Rating	Apr. 28	MT
BofA Cuts Price Target on Harmony Biosciences to $32 From $33	Apr. 21	MT
Mizuho Adjusts PT on Harmony Biosciences Holdings to $44 From $42, Maintains Outperform Rating	Mar. 17	MT
UBS Adjusts Price Target on Harmony Biosciences to $55 From $56, Keeps Buy Rating	Feb. 27	MT
Deutsche Bank Adjusts Harmony Biosciences Price Target to $52 From $55, Maintains Buy Rating	Feb. 20	MT
Mizuho Adjusts Price Target on Harmony Biosciences to $42 From $52, Keeps Outperform Rating	Feb. 20	MT
Deutsche Bank Initiates Coverage on Harmony Biosciences With Buy Rating, $55 Price Target	Feb. 11	MT
BofA Adjusts Price Target on Harmony Biosciences to $31 From $32	Feb. 03	MT
HC Wainwright Initiates Harmony Biosciences at Buy With $75 Price Target	Dec. 17	MT
UBS Initiates Harmony Biosciences Holdings at Buy With $56 Price Target	24-09-10	MT
Mizuho Securities Adjusts Harmony Biosciences Price Target to $42 From $40, Maintains Outperform Rating	24-08-07	MT
Citigroup Initiates Harmony Biosciences at Buy Rating With $48 Price Target	24-06-21	MT
Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	24-02-27	MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	24-02-23	MT
Mizuho Boosts PT on Harmony Biosciences to $42 From $33 Ahead of Q4 2023 Earnings Announcement, Maintains Buy Rating	24-02-15	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $28 From $25, Maintains Sell Rating	24-01-09	MT
BofA Securities Downgrades Harmony Biosciences Holdings to Underperform From Neutral	24-01-02	MT
Mizuho Raises Price Target on Harmony Biosciences to $33 From $28 on 'Continued Commercial Execution', Reiterates Buy Rating	23-11-06	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $27 From $26, Maintains Outperform Rating	23-11-01	MT
Mizuho Slashes Price Target on Harmony Biosciences to $28 From $54, Keeps Buy Rating	23-10-19	MT
Needham Cuts Price Target on Harmony Biosciences to $53 From $66, Keeps Buy Rating	23-10-16	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $26 From $58, Keeps Outperform Rating	23-10-16	MT
Goldman Sachs Downgrades Harmony Biosciences Holdings to Sell From Neutral, Cuts Price Target to $31 From $40	23-09-25	MT
Berenberg Initiates Coverage on Harmony Biosciences at Buy, $59 Price Target	23-09-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Analyst Reco.

Filters